The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Updates from the LocoMMotion study
In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some updates on the LocoMMotion study (NCT04035226). Prof. Einsele first discusses the overall survival (OS) and progression-free survival (PFS) observed, which further highlight the limited success of current treatment approaches and the importance of further investigating novel immunotherapies such as CAR-T therapy and bispecific antibodies in patients with relapsed/refractory (R/R) myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
